Department of Error (DOI:10.1016/S0140-6736(06)68350-5);Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study

Lancet

Volumn 367, Issue 9516, 2006, Pages 1057-1065

  Winblad, Bengt ^a   Kilander, Lena ^b   Eriksson, Sture ^c   Minthon, Lennart ^d   Båtsman, Stellan ^e   Wetterholm, Anna Lena ^f   Jansson Blixt, Catarina ^f   Haglund, Anders ^f  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c UMEÅ UNIVERSITY   (Sweden)

^d LUND UNIVERSITY   (Sweden)

^e Kalix Vårdcentral ^*  (Sweden)

^f PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIANEMIC AGENT; ANTIDEPRESSANT AGENT; ANTIGOUT AGENT; ANTIINFECTIVE AGENT; ANTIRHEUMATIC AGENT; ANXIOLYTIC AGENT; DIURETIC AGENT; DONEPEZIL; HYPNOTIC AGENT; LAXATIVE; NEUROLEPTIC AGENT; PLACEBO; SEDATIVE AGENT; CHOLINESTERASE INHIBITOR; INDAN DERIVATIVE; PIPERIDINE DERIVATIVE;

AGED; ALZHEIMER DISEASE; ANEMIA; ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; GOUT; HALLUCINATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL STAFF; MINI MENTAL STATE EXAMINATION; NURSING HOME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SWEDEN; TREATMENT OUTCOME; CLASSIFICATION; DRUG EFFECT; HOSPITALIZATION; MIDDLE AGED;

ACTIVITIES OF DAILY LIVING; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COGNITION; DOUBLE-BLIND METHOD; HUMANS; INDANS; MIDDLE AGED; NURSING HOMES; PIPERIDINES; SEVERITY OF ILLNESS INDEX;

EID: 33645741379     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)69698-0     Document Type: Erratum

References (29)

1. Aguero-Torres H., Fratiglioni L., and Winblad B. Natural history of Alzheimer's disease and other dementias: review of the literature in the light of the findings from the Kungsholmen Project. Int J Geriatr Psychiatry 13 (1998) 755-766
2. Wilcock G., Lilienfeld S., and Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. BMJ 321 (2000) 1445-1449
3. Whitehead A., Perdomo C., Pratt R., Birks J., Wilcock G., and Evans J. Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials. Int J Geriatr Psychiatry 19 (2004) 624-633
4. Ritchie C., Ames D., Clayton T., and Lai R. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. Am J Geriatr Psychiatry 12 (2004) 358-369
5. National Institute for Health and Clinical Excellence. Appraisal consultation document: donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease. http://www.nice.org.uk/page.aspx?o=288878 (accessed March 3, 2006)
6. Tariot P., Cummings J., Katz I., et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 49 (2001) 1590-1599
7. Feldman H., Gauthier S., Hecker J., Vellas B., Subbiah P., and Whalen E. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 57 (2001) 613-620
8. Tariot P., Farlow M., Grossberg G., Graham S., McDonald S., and Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291 (2004) 317-324
9. Reisberg B., Doody R., Stoffler A., Schmitt F., Ferris S., and Mobius H. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348 (2003) 1333-1341
10. Winblad B., and Poritis N. Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 14 (1999) 135-146
11. Folstein M., Folstein S., and McHugh P. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 (1975) 189-198
12. Sclan S., and Reisberg B. Functional assessment staging (FAST) in Alzheimer's disease: reliability, validity, and ordinality. Int Psychogeriatr 4 suppl 1 (1992) 55-69
13. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edn. (1994), American Psychiatric Association, Washington
14. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 (1984) 939-944
15. Panisset M., Roudier M., Saxton J., and Boller F. Severe impairment battery: a neuropsychological test for severely demented patients. Arch Neurol 51 (1994) 41-45
16. Schmitt F., Ashford W., Ernesto C., et al. The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. Alzheimer Dis Assoc Disord 11 suppl 2 (1997) S51-S56
17. Galasko D., Bennett D., Sano M., et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. Alzheimer Dis Assoc Disord 11 suppl 2 (1997) S33-S39
18. Galasko D., Schmitt F., Jin S., et al. Detailed assessment of cognition and activities of daily living in moderate to severe Alzheimer's disease. Neurobiol Aging 21 suppl 1 (2000) S168
19. Cummings J., Mega M., Gray K., Rosenberg-Thompson S., Carusi D., and Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44 (1994) 2308-2314
20. CGI Clinical Global Impressions. ECDEU assessment manual for psychopharmacology (1976), US Dept of Health, Education, and Welfare, Rockville Publication ADM 76-338
21. Anon. COSTART-coding symbols for thesaurus of adverse reaction terms (1989), US Food and Drug Administration, Rockville
22. Davis K., Mohs R., Marin D., et al. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 281 (1999) 1401-1406
23. Lopez O., Becker J., Wisniewski S., Saxton J., Kaufer D., and DeKosky S. Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J Neurol Neurosurg Psychiatry 72 (2002) 310-314
24. Feldman H., Gauthier S., Hecker J., et al. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. J Am Geriatr Soc 51 (2003) 737-744
25. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 1 (2006) CD005593
26. Rogers S., Farlow M., Doody R., Mohs R., and Friedhoff L. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 50 (1998) 136-145
27. Burns A., Rossor M., Hecker J., et al. The effects of donepezil in Alzheimer's disease: results from a multinational trial. Dement Geriatr Cogn Disord 10 (1999) 237-244
28. Winblad B., Engedal K., Soininen H., et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 57 (2001) 489-495
29. Pratt R., Perdomo C., Surick I., and Ieni J. Donepezil: tolerability and safety in Alzheimer's disease. Int J Clin Pract 56 (2002) 710-777